Supervised lifestyle intervention from a medical professional may help maximize fat loss and minimize muscle tissue loss in people taking the potent weight loss drugs.

Both glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and sodium-glucose cotransporter-2 inhibitors (SGLT2is) are ...

A real-world study finds cardiovascular and survival benefits from dual therapy in patients with type 2 diabetes.

Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for the treatment of cardiometabolic and inflammatory diseases, today announced ...

Combination therapy with GLP-1 RAs and thiazolidinediones is associated with a reduced risk for mortality in patients with T2D, a study finds.

Pooled annual prevalence of GLP-1 RA use was 0.1 percent from 2018 to 2021 and increased to 0.4 percent by 2022.

Pooled annual prevalence of GLP-1 RA use was 0.1 percent from 2018 to 2021 and increased to 0.4 percent by 2022. (HealthDay News) — Among U.S. adults without diabetes, the use of glucagon-like ...

The 5-year unadjusted cumulative incidence of death-censored graft loss from a cohort matched on survival time before GLP-1 RA initiation was 6.0% for GLP-1 RA users and 10.7% for nonusers.

Cade Shadbolt, from the University of Melbourne in Australia, and colleagues examined data from the Medical Expenditure Panel Survey Household Component from 2018 to 2022 to examine GLP-1 RA use ...

Shelf-stable vaccine patch maker Vaxess Technologies announced today that it received an additional $9 million in funding.

(MENAFN- ACN NewsWire) Hebe Biotechnology Appoints Industry Insider Dr. Hannes Hentze as Chief Development Officer to Advance Next-Generation GLP-1 RA Weight Loss Therapy SINGAPORE, Apr 10 ...